Last week, PCVX had pneumococcal vaccine data that could seriously challenge PFE’s market leading Prevnar 20. TVTX celebrated full FDA approval of its IgAN drug, just in time for new KDIGO guidelines.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.